Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, bolstering the drug’s case against AstraZeneca’s competing treatments …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
COVID-19 disrupts TB diagnostic services in South Africa’s primary health clinics, highlighting the need for robust systems resilient to future pandemics.
The FDA has approved a second gene therapy for adults with hemophilia B, drugmaker Pfizer announced on Friday. The approval of fidanacogene elaparvovec (Beqvez) stipulates
Researchers have discovered that DNA methylation is crucial for reprogramming astrocytes into stem cells in the adult mouse brain, especially after ischemic injury, with potential